Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
Read original at benzingaStocks · News reference
8-K filing — TuHURA Biosciences, Inc./NV (HURA)
Filed: 2026-08-21 AccNo: 0001193125-26-361272 Size: 168 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 21, 2026, 9:00 PM
- Checked
- Aug 21, 2026, 9:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share
Read original at benzingaTuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia
Read original at benzinga